A pediatric prognostic score for patients undergoing allogeneic hematopoietic stem cell transplantation

被引:7
|
作者
Arndt, Clemens [1 ]
Beck, James F. [1 ]
Gruhn, Bernd [1 ]
机构
[1] Jena Univ Hosp, Dept Pediat, Sect Hematol & Oncol, D-07740 Jena, Germany
关键词
hematopoietic stem cell transplantation; children; score; serum ferritin; cholinesterase; disease risk; ACUTE-LEUKEMIA; IRON OVERLOAD; MORTALITY TRM; BONE-MARROW; RISK SCORE; CHILDREN; IMPACT; SCT;
D O I
10.1111/ejh.12390
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The purpose of this study was to find and evaluate risk factors influencing the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in children and to develop a score stratifying patients by their risk of mortality. Methods: We retrospectively analyzed the effects of patient and donor characteristics as well as laboratory data including liver, iron, and inflammation parameters on the overall survival of 131 children and young adults with malignant and non-malignant diseases undergoing allogeneic HSCT. Results: In univariate analysis, 5-yr overall survival decreased significantly in patients with high disease risk (38% vs. 74%, P < 0.001), peripheral blood as graft source (47% vs. 73% for bone marrow, P < 0.001), ferritin >1500 ng/mL (41% vs. 79%, P = 0.001), C-reactive protein >10 mg/L (55% vs. 69%, P = 0.019), lactate dehydrogenase >6 mu M.s (22% vs. 67%, P = 0.001), gamma-glutamyl transpeptidase >1 mu M.s (43% vs. 68%, P = 0.035), and cholinesterase < 60 mu M.s (36% vs. 70%, P = 0.002). For HLA recipient-donor match, there was a 5-yr overall survival of 81% for matched related, 58% for matched unrelated, 56% for mismatched unrelated, and 50% for haploidentical related donors (P = 0.020). We subsequently developed a score of parameters significant in multivariate analysis, that is, disease risk (HR = 4.1, P = 0.027), ferritin (HR = 6.4, P = 0.002), and cholinesterase (HR = 5.3, P = 0.027). For this score, 5-yr overall survival was 92% for the low-risk group, 66% for the intermediate-risk group, and 17% for the high-risk group (P < 0.001). Conclusions: Disease risk, ferritin, and cholinesterase are factors decisively influencing the prognosis after HSCT and should be evaluated in further trials.
引用
收藏
页码:509 / 515
页数:7
相关论文
共 50 条
  • [21] Assessment of Prognostic Factors, Colonization, and Infection Epidemiology in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    Strzalka, Piotr
    Krawiec, Kinga
    Stanczak, Kamila
    Czemerska, Magdalena
    Pluta, Agnieszka
    Wierzbowska, Agnieszka
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S515 - S516
  • [22] Prognostic Impact of Splicing Factor Mutations in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    Panagiota, Victoria
    Heuser, Michael
    Cruz, Michelle Maria Araujo
    Badbaran, Anita
    Shahswar, Rabia
    Triviai, Ioanna N.
    Fehse, Boris
    Alchalby, Haefaa
    Lehmann, Ulrich
    Koenecke, Christian
    Chaturvedi, Anuhar
    Stadler, Michael
    Eder, Matthias
    Goehring, Gudrun
    Koenigsmann, Michael
    Schlegelberger, Brigitte
    Kreipe, Hans Heinrich
    Ganser, Arnold
    Thol, Felicitas
    Kroeger, Nicolaus
    BLOOD, 2014, 124 (21)
  • [23] Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis
    Michaela Döring
    Ulrike Hartmann
    Annika Erbacher
    Peter Lang
    Rupert Handgretinger
    Ingo Müller
    BMC Infectious Diseases, 12
  • [24] Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis
    Doering, Michaela
    Hartmann, Ulrike
    Erbacher, Annika
    Lang, Peter
    Handgretinger, Rupert
    Mueller, Ingo
    BMC INFECTIOUS DISEASES, 2012, 12
  • [25] Prognostic Significance of Quality of Life in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
    Hamilton, Betty K.
    Rybicki, Lisa
    Abounader, Donna M.
    Dabney, Jane
    Dean, Robert M.
    Duong, Hien K.
    Hill, Brian T.
    Gerds, Aaron
    Jagadeesh, Deepa
    Kalaycio, Matt E.
    Lawrence, Christine
    McLellan, Linda
    Pohlman, Brad
    Sobecks, Ronald M.
    Bolwell, Brian J.
    Majhail, Navneet S.
    BLOOD, 2014, 124 (21)
  • [26] Sequelae of pediatric allogeneic hematopoietic stem cell transplantation
    Diamond, C.
    Oeffinger, K.
    Hall, R.
    Driscoll, T.
    Cardones, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : B10 - B10
  • [27] Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation
    ten Brink, Marloes H.
    Ackaert, Oliver
    Zwaveling, Juliette
    Bredius, Robbert G. M.
    Smiers, Frans J.
    den Hartigh, Jan
    Lankester, Arjan C.
    Guchelaar, Henk-Jan
    THERAPEUTIC DRUG MONITORING, 2014, 36 (04) : 465 - 472
  • [28] HETEROGENEOUS PSYCHOLOGICAL ASPECTS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Kachaamy, Eliana
    Zahran, Kamal
    Ibrahim, Ahmad
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 660 - 660
  • [29] Importance of Parenteral Nutrition in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    Skop-Lewandowska, Agata
    Kolarzyk, Emilia
    Skotnicki, Aleksander B.
    ONKOLOGIE, 2011, 34 (04): : 210 - 212
  • [30] Nutrition status and management of patients undergoing allogeneic hematopoietic stem cell transplantation
    Osborne, Jacqueline
    Cassar, Olivia
    Wittholz, Kym
    Griffin, Hilda
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 259 - 259